Financials data is unavailable for this security.
View more
Year on year Jinyu Bio-Technology Co Ltd grew revenues 4.55% from 1.53bn to 1.60bn while net income improved 34.63% from 210.68m to 283.63m.
| Gross margin | 54.60% |
|---|---|
| Net profit margin | 11.97% |
| Operating margin | 13.20% |
| Return on assets | 2.36% |
|---|---|
| Return on equity | 3.07% |
| Return on investment | 2.74% |
More ▼
Cash flow in CNYView more
In 2023, cash reserves at Jinyu Bio-Technology Co Ltd fell by 213.90m. However, the company earned 414.83m from its operations for a Cash Flow Margin of 25.96%. In addition the company generated 111.38m cash from financing while 740.11m was spent on investing.
| Cash flow per share | -- |
|---|---|
| Price/Cash flow per share | -- |
| Book value per share | 4.84 |
|---|---|
| Tangible book value per share | 4.19 |
More ▼
Balance sheet in CNYView more
| Current ratio | 3.53 |
|---|---|
| Quick ratio | 3.12 |
| Total debt/total equity | 0.0081 |
|---|---|
| Total debt/total capital | 0.0079 |
More ▼
Growth rates in CNY
Year on year, both dividends per share and earnings per share excluding extraordinary items growth increased 33.33% and 37.28%, respectively. The positive trend in dividend payments is noteworthy since very few companies in the Major Drugs industry pay a dividend. Additionally when measured on a five year annualized basis, both dividend per share and earnings per share growth ranked below the industry average relative to its peers.
| Div yield(5 year avg) | 0.57% |
|---|---|
| Div growth rate (5 year) | -25.56% |
| Payout ratio (TTM) | 54.21% |
| EPS growth(5 years) | -16.94 |
|---|---|
| EPS (TTM) vs TTM 1 year ago | -43.54 |
More ▼
